Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-11

Compass Therapeutics (CMPX)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$5,097,150
Thomas Schuetz total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
98.5%
Say-on-pay support, latest vote
Companies that benchmark against CMPX
3 companies name CMPX as a compensation peer

Each company listed discloses CMPX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CMPX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Thomas Schuetz$630,000$381,150$0$4,065,000$0$0$21,000$5,097,150
Chief Executive Officer
Jonathan Anderman450,000198,000758,8001,427,800
General Counsel and Corporate Secretary
Barry Shin480,000216,0000677,5000021,0001,394,500
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Thomas Schuetz$5,097,150$3,093,057+2,004,093
Jonathan Anderman1,427,800893,635+534,165
Barry Shin1,394,500

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Thomas SchuetzRSU478,125$2,567,531
Barry ShinRSU300,0001,611,000
Thomas SchuetzRSU250,0001,342,500
Thomas SchuetzOption29,1362.4
Thomas SchuetzOption204,1443.93
Thomas SchuetzOption332,0371.93
Thomas SchuetzOption1,187,5003.65
Barry ShinOption300,0001.65
Barry ShinOption197,9103.65
Jonathan AndermanOption2,0682.4
Jonathan AndermanOption23,3223.93
Jonathan AndermanOption43,3261.57
Jonathan AndermanOption200,0001.2
Jonathan AndermanOption221,6603.65
05

Incentive-plan design — the Compensation Discussion & Analysis

The company's compensation program reflects its growth and corporate goals, utilizing a combination of base salary, annual cash bonus, and long-term equity incentive compensation to align executive interests with stockholders in both the short- and long-term. The Board targets being competitive to peer companies and utilizes independent, third-party benchmarking to inform the level and mix of compensation.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultantAlpine Rewards
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-10117,963,6841,796,0222,061,97798.5%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1098.5%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Carl L. GordonIndependent · Board Chair · Compensation (Chair)$65,000$0$108,400$173,400
Ellen V. ChiniaraIndependent · Audit · Nominating and Corporate Governance60,0000108,400168,400
Richard S. LindahlIndependent · Audit (Chair)55,0000108,400163,400
Philip J. FerneauIndependent · Nominating and Corporate Governance (Chair) · Compensation55,0000108,400163,400
James P. BoylanIndependent · Audit50,0000108,400158,400
Mary Ann GrayIndependent · Compensation45,0000108,400153,400
Thomas J. SchuetzEmployee director0
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)10,000 / 12,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$330,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$330,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Compass Therapeutics2025Thomas Schuetz$630,000$0$4,065,000$0$5,097,150

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Thomas SchuetzDEF 14A2026-04-290001140361-26-017649Section “Executive Compensation”. As printed: 5,097,150. Filing ↗machine: r2 · c21 · span 303582–303591
2Section 01, Jonathan AndermanDEF 14A2026-04-290001140361-26-017649Section “Executive Compensation”. As printed: 1,427,800. Filing ↗
3Section 01, Barry ShinDEF 14A2026-04-290001140361-26-017649Section “Executive Compensation”. As printed: 1,394,500. Filing ↗machine: r4 · c21 · span 311426–311435
4Section 08, Carl L. GordonDEF 14A2026-04-290001140361-26-017649Section “Director Compensation”. As printed: 173,400. Filing ↗machine: span 268365–268544
5Section 08, Ellen V. ChiniaraDEF 14A2026-04-290001140361-26-017649Section “Director Compensation”. As printed: 168,400. Filing ↗machine: span 265807–265986
6Section 08, Richard S. LindahlDEF 14A2026-04-290001140361-26-017649Section “Director Compensation”. As printed: 163,400. Filing ↗machine: span 275211–275389
7Section 08, Philip J. FerneauDEF 14A2026-04-290001140361-26-017649Section “Director Compensation”. As printed: 163,400. Filing ↗machine: span 270575–270754
8Section 08, James P. BoylanDEF 14A2026-04-290001140361-26-017649Section “Director Compensation”. As printed: 158,400. Filing ↗machine: span 273134–273313
9Section 08, Mary Ann GrayDEF 14A2026-04-290001140361-26-017649Section “Director Compensation”. As printed: 153,400. Filing ↗machine: span 263614–263793
10Section 08, Thomas J. SchuetzDEF 14A2026-04-290001140361-26-017649Section “Director Compensation”. As printed: 0. Filing ↗
11Section 06, 2026 voteForm 8-K2026-06-110001171843-26-004068Item 5.07 · say-on-pay result. As reported: 98.5% (votes for as printed: 117,963,684). Filing ↗
12Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
13Section 09b board cost (computed)ComputedcomputedCash 330,000 + equity 0 + all other 0 = 330,000, summed across the director compensation table rows.machine: formula: Σ = 330,000
14Compass Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-290001140361-26-017649CEO total compensation as printed in Compass Therapeutics's own proxy. As printed: 5,097,150. Filing ↗machine: r2 · c21 · span 303582–303591